CHANDAN Chandan Healthca Q3 FY26 results (Oct–Dec 2025) and concall
Chandan Healthcare Limited reported a strong Q3 FY26 with revenue growing 20% YoY to ₹65.77 crores and EBITDA up 39% YoY to ₹12.61 crores, driven by robust B2C diagnostic sales. EBITDA margins expanded significantly to 19.17%. However, PAT margin saw a slight dip to 6.9% due to a one-time gratuity provision. The company is aggressively expanding its network of labs and comprehensive centers, with plans for specialized diagnostics and a major government project, and expects higher growth and improved margins in the coming periods.
You’re reading a preview. Opening the full call uses 1 concall credit.
Sign in to use your monthly call allowance.
What they filed
Q3 FY26: revenue up 19.0%, net profit up 8.1% against the same quarter last year.
| Line item | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 |
|---|---|---|---|---|---|---|
| Revenue | 110 | 55 | 63 | 68 | 68 −38% | 65 +19% |
| EBITDA | 20 | 9 | 10 | 14 | 14 −29% | 12 +33% |
| Net profit | 11 | 4 | 6 | 6 | 8 −29% | 5 +8% |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Inve summary of a publicly available earnings call transcript; see how call summaries are prepared. Not investment advice.
